

PTQ-1449 REPRODUCED

ATTORNEY DOCKET NO.  
3506.1002-003APPLICATION NO.  
10/817,332INFORMATION DISCLOSURE CITATION  
IN AN APPLICATIONFIRST NAMED INVENTOR  
Steven B. LandauFILING DATE  
April 2, 2004

May 12, 2004

EXAMINER  
UnknownCONFIRMATION NO.  
UnknownGROUP  
Unknown

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AA	4,695,568	09-22-1987	Ninomiya, <i>et al.</i>
	AB	5,225,407	07-06-1993	Oakley, <i>et al.</i>
	AC	5,352,685	10-04-1994	Maruyama, <i>et al.</i>
	AD	5,663,343	09-02-1997	van der Meij, <i>et al.</i>
	AE	5,945,415	08-31-1999	Kato, <i>et al.</i>
	AF	5,962,494	10-05-1999	Young
	AG	5,977,127	11-02-1999	Bonnacker, <i>et al.</i>
	AH	6,300,336 B1	10-09-2001	Eeckhout, <i>et al.</i>
	AI	6,440,453 B1	08-27-2002	Fischer, <i>et al.</i>
	AJ	US 2002/0010216 A1	01-24-2002	Rogosky, <i>et al.</i>
	AK	US 2002/0107249 A1	08-08-2002	Wong, <i>et al.</i>
	AA2	US 2003/0158221 A1	08-21-2003	Zhang, <i>et al.</i>
	AB2	US 2003/0203055 A1	10-30-2003	Rao, <i>et al.</i>
	AC2	6,465,458 B1	10-15-2002	Wong, <i>et al.</i>
	AD2	6,355,647 B1	03-12-2002	Steiner, <i>et al.</i>
	AE2	4,939,136	07-03-1990	Haeck, <i>et al.</i>
	AF2	US 2001/0020025 A1	09-06-2001	Megens
	AG2	US 2002/0002197 A1	01-03-2002	Mueller, <i>et al.</i>
	AH2			
	AI2			
	AJ2			
	AK2			
	AA3			
	AB3			
	AC3			

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.  
3506.1002-003APPLICATION NO.  
10/817,332FIRST NAMED INVENTOR  
Steven B. LandauFILING DATE  
April 2, 2004EXAMINER  
UnknownCONFIRMATION NO.  
UnknownGROUP  
UnknownINFORMATION DISCLOSURE  
IN AN APPLICATION

May 12, 2004

MAY 17 2004

(Use several sheets if necessary)

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION	
					YES	NO
	AL	WO 01/26623 A3	04-19-2001	Laxdale Limited		
	AM	WO 03/063873 A1	08-07-2003	Arachnova Therapeutics Ltd.		
	AN	WO 00/48581 A3	08-24-2000	Novartis AG		
	AO	WO 02/094249 A1	11-28-2002	Arachnova Therapeutics Ltd.		
	AP	WO 03/077897 A1	09-25-2003	Cypress Bioscience, Inc.		
	AQ	WO 2004/004734 A1	01-15-2004	Arachnova Therapeutics Ltd.		
	AL2	WO 98/50037	11-12-1998	Mitsubishi Chemical Corporation		X
	AM2	WO 03/061657 A1	07-31-2003	Aryx Therapeutics		
	AN2	WO 2004/019948 A1	03-11-2004	Arachnova Therapeutics Ltd.		
	AO2					
	AP2					
	AQ2					
	AL3					
	AM3					
	AN3					
	AO3					
	AP3					
	AQ3					
	AL4					
	AM4					
	AN4					
	AO4					
	AP4					
	AQ4					

EXAMINER

DATE CONSIDERED

PTQ-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  May 12, 2004  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3506.1002-003		APPLICATION NO. 10/817,332	
	FIRST NAMED INVENTOR Steven B. Landau		FILING DATE April 2, 2004	
	EXAMINER Unknown	CONFIRMATION NO. Unknown	GROUP Unknown	


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AR	Andersson, K.E., "Treatment of the Overactive Bladder: Possible Central Nervous System Drug Targets," <i>Urology</i> , 59 (Suppl 5A):18-24 (2002).	
AS	Andersson, K.E., "Bladder Activation: Afferent Mechanisms," <i>Urology</i> , 59 (Suppl 5A):43-50 (2002).	
AT	Morrison, J. <i>et al.</i> , "Neurophysiology and Neuropharmacology" In: Incontinence (vol. 2) Abrams, P., Cardozo, L., Khoury, S., and Wein, A., Eds. (UK, Health Publications, Ltd.,) pp. 83-163 (2002).	
AU	Owens, M. J. <i>et al.</i> , "Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and their Metabolites <sup>1</sup> ," <i>J. Pharmacol. Exp. Ther.</i> , 283(3): 1305-1322 (1997).	
AV	Sharma, A. <i>et al.</i> , "Pharmacokinetics and Safety of Duloxetine, a Dual-Serotonin and Norepinephrine Reuptake Inhibitor," <i>J. Clin. Pharmacol.</i> , 40:161-167 (2000).	
AW	Thor, K. B. <i>et al.</i> "Effects of Duloxetine, a Combined Serotonin and Norepinephrine Reuptake Inhibitor, on Central Neural Control of Lower Urinary Tract Function in the Chloralose-Anesthetized Female Cat," <i>J. Pharmacol. Exp. Ther.</i> , 274: 1014-1024 (1995).	
AX	Downie, J.W., "Pharmacological Manipulation of Central Micturition Circuitry," <i>Curr. Opin. CPNS Inves. Drugs</i> , 1(2):231-239 (1999).	
AY	Khan, M.A. <i>et al.</i> , "Doxazosin Modifies Serotonin-Mediated Rabbit Urinary Bladder Contraction. Potential Clinical Relevance," <i>Urol. Res.</i> , 28:116-121 (2000).	
AZ	Metts, J. F., "Interstitial Cystitis: Urgency and Frequency Syndrome," <i>American Family Physician</i> , 64(7): 1199-1206 (2001).	
AR2	Theoharides, T. C. and Sant, G.R., "New Agents for the Medical Treatment of Interstitial Cystitis," <i>Exp. Opin. Invest. Drugs</i> , 10(3): 521-546 (2001).	
AS2	Collins M.M. <i>et al.</i> , "How Common is Prostatitis? A National Survey of Physician Visits," <i>J. Urol.</i> , 159:1224-1228 (1998).	
AT2	Eguchi, J. <i>et al.</i> , "Pharmacological Profile of the Novel Antidepressant 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno-[2,3-d]pyrimidine Monohydrate Hydrochloride," <i>Arzneim.-Forschung/Drug Res.</i> , 47(12): 1337-47 (1997).	
AU2	Wood, J.D. <i>et al.</i> "Fundamentals of Neurogastroenterology," <i>Gut</i> , 45(Suppl II):II6-II16 (1999).	

EXAMINER <i>Kills</i>	DATE CONSIDERED <i>9/2004</i>
--------------------------	----------------------------------

PTQ-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  May 12, 2004  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3506.1002-003  FIRST NAMED INVENTOR Steven B. Landau  EXAMINER Unknown	APPLICATION NO. 10/817,332  FILING DATE April 2, 2004  CONFIRMATION NO. Unknown GROUP Unknown
--	---	--

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

M	AV2 Center for Drug Evaluation and Research Application Number: 020623; Pharmacology Reviews; July 5, 1996.
	AW2 Kilpatrick, G.J. <i>et al.</i> , "Identification and Distribution of 5-HT <sub>2</sub> Receptors in Rat Brain Using Radioligand Binding," <i>Nature</i> , 330: 746-748 (1987).
M	AX2 Butler, A. <i>et al.</i> , "Pharmacological Properties of GR38032F, a Novel Antagonist at 5-HT <sub>2</sub> Receptors," <i>Br. J. Pharmacol.</i> , 94(2): 397-412 (1988).
	AY2 Ito, C. <i>et al.</i> , "Effect of GK-128 [2-[(2-Methylimidazol-1-yl)methyl]-benzo[f]thiochromen-1-one Monohydrochloride Hemihydrate], a Selective 5-Hydroxytryptamine, Receptor Antagonist, on Colonic Function in Rats," <i>J. Pharmacol. Exp. Ther.</i> , 280(1): 67-72 (1997).
M	AZ2 Chuang, Y.C. <i>et al.</i> , "Intravesical Protamine Sulfate and Potassium Chloride as a Model for Bladder Hyperactivity," <i>Urology</i> , 61(3): 664-670 (2003).
	AR3 Sasaki, K. <i>et al.</i> , "Diabetic Cystopathy Correlates with a Long-Term Decrease in Nerve Growth Factor Levels in the Bladder and Lumbosacral Dorsal Root Ganglia," <i>J. Urol.</i> , 168(3): 1259-1264 (2002).
	AS3 Yoshimura, N. and Chancellor, M. B., "Current and Future Pharmacological Treatment for Overactive Bladder," <i>J. Urol.</i> , 168:1897-1913 (2002).
M	AT3 Appell, R. A. <i>et al.</i> , "Prospective Randomized Controlled Trial of Extended-Release Oxybutynin Chloride and Tolterodine Tartrate in the Treatment of Overactive Bladder: Results of the OBJECT Study," <i>Mayo Clin. Proc.</i> 76:358-363 (2001).
	AU3 Elmiron® (pentosan polysulfate sodium), capsules, <i>Product Information</i> , Ortho-McNeil Pharmaceutical, Inc., Raritan, N.J. (2002).
M	AV3 Elliott, D. S. <i>et al.</i> , "Medical Management of Overactive Bladder," <i>Mayo Clin. Proc.</i> 76:353-355 (2001).
	AW3 Tonini, M. <i>et al.</i> , "Characterization of the 5-HT Receptor Potentiating Neuromuscular Cholinergic Transmission in Strips of Human Isolated Detrusor Muscle," <i>Br. J. Pharmacol.</i> , 113(1):1-2 (1994).
M	AX3 Espey, M.J. <i>et al.</i> , "Serotonergic Modulation of Spinal Ascending Activity and Sacral Reflex Activity Evoked by Pelvic Nerve Stimulation in Cats," <i>Brain Res.</i> , 798(1-2):101-108 (1998).

EXAMINER 	DATE CONSIDERED 9/2004
---	---------------------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  May 12, 2004  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3506.1002-003	APPLICATION NO. 10/817,332	
	FIRST NAMED INVENTOR Steven B. Landau		FILING DATE April 2, 2004
	EXAMINER Unknown	CONFIRMATION NO. Unknown	GROUP Unknown

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**


AY3	Yoshida, A. <i>et al.</i> , "5-Hydroxytryptamine Receptors, Especially the 5-HT <sub>4</sub> Receptor, in Guinea Pig Urinary Bladder," <i>Jpn. J. Pharmacol.</i> , 89(4):349-355 (2002).
AZ3	Kodama, M. and Takimoto, Y., "Influence of 5-Hydroxytryptamine and the Effect of a New Serotonin Receptor Antagonist (Sarpogrelate) on Detrusor Smooth Muscle of Streptozotocin-Induced Diabetes Mellitus in the Rat," <i>International Journal of Urology</i> 7:231-235 (2000).
AR4	Katofiasc, M. A. <i>et al.</i> , "Comparison of the Effects of Serotonin Selective, Norepinephrine Selective, and Dual Serotonin and Norepinephrine Reuptake Inhibitors on Lower Urinary Tract Function in Cats," <i>Life Sci.</i> , 71:1227-1236 (2002).
AS4	Andersson, K. E., "Treatment of Overactive Bladder: Other Drug Mechanisms," <i>Urology</i> , 55(Supplement 5A):51-59 (2000).
AT4	Testa, R. <i>et al.</i> , "Effect of Different 5-Hydroxytryptamine Receptor Subtype Antagonists on the Micturition Reflex in Rats," <i>BJU Int.</i> , 87(3):256-264 (2001).
AU4	Barras, M. <i>et al.</i> , "Characterisation of the 5-HT Receptor Potentiating Neurotransmission in Rabbit Bladder," <i>Eur. J. Pharmacol.</i> , 318(2-3):425-428 (1996).
AV4	Eguchi, J. <i>et al.</i> , "The Anxiolytic-like Effect of MCI-225, a Selective NA Reuptake Inhibitor with 5-HT <sub>4</sub> Receptor Antagonism," <i>Pharm., Biochem. and Behavior</i> 68:677-683 (2001).
AW4	Burns, M. J.; The Pharmacology and Toxicology of Reboxetine, [Retrieved from the Internet 2002-12-04]. Retrieved from the Internet < <a href="http://www.ijmt.net/3_4/3_4_26.html">http://www.ijmt.net/3_4/3_4_26.html</a> >.
AX4	Bymaster, F. P. <i>et al.</i> , "Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters <i>in vitro</i> and <i>in vivo</i> , Human Serotonin Receptor Subtypes, and Other Neuronal Receptors," <i>Neuropharmacol.</i> , 25(6):871-880 (2001).
AY4	Béïque, J.-C. <i>et al.</i> , "Affinities of Venlafaxine and Various Reuptake Inhibitors for the Serotonin and Norepinephrine Transporters," <i>Eur. J. Pharmacol.</i> , 349:129-132 (1998).
AZ4	Wong, E. H. F. <i>et al.</i> , "Reboxetine: A Pharmacologically Potent, Selective, and Specific Norepinephrine Reuptake Inhibitor," <i>Biol. Psych.</i> , 47(9):818-829 (2000).
AR5	Fairweather, D. B. <i>et al.</i> , "The Psychomotor and Cognitive Effects of Litoxetine in Young and Middle Aged Volunteers," <i>Br. J. Clin. Pharmacol.</i> 40:119-125 (1995).

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  May 12, 2004  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3506.1002-003		APPLICATION NO. 10/817,332	
	FIRST NAMED INVENTOR Steven B. Landau		FILING DATE April 2, 2004	
	EXAMINER Unknown	CONFIRMATION NO. Unknown	GROUP Unknown	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
AS5	LOTROXEX (alosetron hydrochloride) - Tablets, <i>Product Information</i> , GlaxoSmithKline, Research Triangle Park, NC, pp. 1-13 (2002).
AT5	GB 0216027.3 filed 07-10-2002, entitled "New Therapeutic Use," priority document for WO 2004/004734 A1 (Reference AQ).
AU5	GB 0220064.0 filed 08-29-2002, entitled "New Therapeutic Use," priority document for WO 2004/019948 A1 (Reference AN2).
AV5	GB 0316115.5 filed 07-09-2003, entitled "New Therapeutic Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperziny) Thieno[2,3-D] Pyrimidine," priority document for WO 2004/019948 A1 (Reference AN2).
AW5	GB 0304648.9 filed 02-28-2003, entitled "New Therapeutic Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperziny) Thieno [2,3-D] Pyrimidine," priority document for WO 2004/004734 A1 (Reference AQ).
AX5	U.S. Provisional Application No. 60/364,531 filed 03-15-2002, entitled "Methods of Treating Visceral Pain Syndromes," by Rao <i>et al.</i> , priority document for WO 03/077897 A1 (Reference AP) and U.S. 2003/0203055 A1 (Reference AB2).
AY5	Chancellor, M.B., "New Frontiers in the Treatment of Overactive Bladder and Incontinence," <i>Reviews in Urology</i> , 4(4): S50-S56 (2002).
AZ5	Evans, R.J., "Treatment Approaches for Interstitial Cystitis: Multimodality Therapy," <i>Reviews in Urology</i> , 4(Suppl. 1): S16-S20 (2002).
AR6	Simon, H. <i>et al.</i> Eds., "Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms", [Retrieved from the Internet 2003-18-03]. Retrieved from the Internet < <a href="http://wellness.ucdavis.edu/medical_conditions_az/prostatichyperplasia71.html">http://wellness.ucdavis.edu/medical_conditions_az/prostatichyperplasia71.html</a> >.

EXAMINER 	DATE CONSIDERED 9/2004
---	---------------------------